Detalhe da pesquisa
1.
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Thorax
; 67(1): 12-8, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21825083
2.
Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
Clin Transl Sci
; 15(4): 899-911, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34877801
3.
Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.
Drug Metab Dispos
; 38(7): 1029-38, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20406853
4.
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Br J Clin Pharmacol
; 70(1): 57-64, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20642548
5.
Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.
Clin Pharmacol Drug Dev
; 9(4): 428-443, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087001
6.
Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects.
Eur J Drug Metab Pharmacokinet
; 45(4): 513-522, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32301064
7.
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Cancer Invest
; 27(7): 756-63, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19440934
8.
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
J Clin Pharmacol
; 48(9): 1014-24, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18635756
9.
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
Br J Clin Pharmacol
; 65(3): 355-63, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17953718
10.
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Clin Pharmacokinet
; 45(8): 821-41, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16884320
11.
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.
J Clin Pharmacol
; 46(8): 855-66, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16855070
12.
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
J Clin Pharmacol
; 46(1): 88-102, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16397288
13.
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
J Clin Oncol
; 20(21): 4303-12, 2002 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12409328
14.
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Clin Cancer Res
; 9(7): 2426-34, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12855614
15.
Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Clin Cancer Res
; 18(11): 3090-9, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496205
16.
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
J Clin Pharmacol
; 51(2): 189-201, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20354234
17.
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
Am J Ther
; 12(1): 22-34, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15662289
18.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Arthritis Rheum
; 52(3): 916-23, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15751090